Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 13/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 10/20 | 0.46 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.46 |
| ▸ | PIK3R1 | P27986 | 5/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14757509 | 1.00 | PIK3CD (0.51) | PIK3CDPIK3CGPIK3R2PIK3R1PIK3CA | |
| SCHEMBL14649177 | 0.93 | PIK3CD (0.53) | PIK3CDPIK3CGPIK3R2PIK3R1PIK3CA | |
| SCHEMBL9884366 | 0.93 | PIK3CD (0.53) | PIK3CDPIK3CGPIK3R2PIK3R1PIK3CA | |
| SCHEMBL14726152 | 0.92 | PIK3CD (0.47) | PIK3CDPIK3CGPIK3R2PIK3R1PIK3CA | |
| SCHEMBL18852727 | 0.91 | PIK3CD (0.60) | PIK3CDPIK3CGPIK3R2PIK3R1PIK3CA | |
| SCHEMBL14667163 | 0.90 | PIK3CD (0.52) | PIK3CDPIK3CGPIK3R2PIK3R1PIK3CA | |
| SCHEMBL14649514 | 0.87 | PIK3CD (0.53) | PIK3CDPIK3CGPIK3R2PIK3R1PIK3CA | |
| SCHEMBL14730015 | 0.87 | PIK3CD (0.46) | PIK3CDPIK3CGPIK3R2PIK3R1PIK3CA | |
| SCHEMBL14649363 | 0.86 | PIK3CD (0.61) | PIK3CDPIK3CGPIK3R2PIK3R1PIK3CA | |
| SCHEMBL17234856 | 0.86 | PIK3CD (0.64) | PIK3CDPIK3CGPIK3R1PIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170137407-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2017-05-18 | — | — | US | disclosed |
| US-20170137407-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2017-05-18 | — | — | US | disclosed |
| US-9546180-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-9546180-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-9115141-B2 | Substituted isoquinolinones and methods of treatment thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9115141-B2 | Substituted isoquinolinones and methods of treatment thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20140288048-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2014-09-25 | — | — | US | disclosed |
| US-20140288048-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2014-09-25 | — | — | US | disclosed |
| US-8785470-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785470-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20130053362-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLKINE, LLC (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053362-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLKINE, LLC (US) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288048-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AKT3, PIK3CA, AKT1 | PIK3CD 5/4885PIK3CG 14/4885PIK3R2 91/4885 |
| US-20130053362-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AKT3, PIK3CA, AKT1 | PIK3CD 5/4885PIK3CG 14/4885PIK3R2 91/4885 |
| US-20170137407-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AKT3, PIK3CA, AKT1 | PIK3CD 5/4885PIK3CG 14/4885PIK3R2 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.